US ar­gues that As­traZeneca's IRA suit 'fares no bet­ter than the oth­er­s'

The De­part­ment of Jus­tice on Wednes­day took a crack at dis­man­tling As­traZeneca’s law­suit over the se­lec­tion of its type 2 di­a­betes drug Farx­i­ga (da­pagliflozin) for drug price ne­go­ti­a­tions, say­ing it “fares no bet­ter than the oth­ers.”

As­traZeneca, which filed its com­plaint in Delaware fed­er­al court in Au­gust, con­test­ed two as­pects of CMS’ guid­ance ex­plain­ing how it planned to se­lect which drugs would be in­clud­ed in the first year of ne­go­ti­a­tions. The British com­pa­ny took is­sue with the way that CMS de­fines “qual­i­fy­ing sin­gle source drug,” with the drug­mak­er say­ing it should en­com­pass “on­ly one NDA or BLA.” It al­so took is­sue with the way CMS de­fined com­pe­ti­tion, say­ing gener­ics don’t need to be mar­ket­ed in a “bona fide” man­ner.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER